RxLaunchOS is UEM's AI-native commercialization operating system for pharmaceutical and biosimilar manufacturers. It connects role plans, evidence, scoring, scenarios, risks, decisions, experts, and execution from the territory to the enterprise.
RxLaunchOS is the product. Asterion is the clearly labeled fictional pharmaceutical company used inside its read-only demonstration.
Evidence · Readiness · Decisions · Action
Use the product
Understand what you are testing
Start with the complete manufacturer workflow, then see how the same launch changes from the territory representative to the commercial executive. These are product explainers—not claims that software can predict approval, revenue, or launch success.
How RxLaunchOS defines context, diagnoses readiness, structures operating-model and RFP choices, compares governed scenarios, records human decisions, and carries them into accountable launch work.
What commercial executives, functional leaders, regional and district leaders, representatives, KAMs, and cross-functional teams need from the same controlled launch record.
Inside the application
These are current RxLaunchOS screens using the clearly labeled, fictional Asterion demonstration company—not conceptual mockups or client results.
Walk through the live fictional demo
Actual product screen
The fictional Asterion launch shows how coverage, evidence adequacy, and CRM readiness become decision signals instead of disconnected activity metrics.
Actual product screen
Assessment coverage, illustrative readiness, evidence confidence, and unresolved gates stay separate so an incomplete plan cannot look falsely precise.
Actual product screen
Fifteen dated milestones connect owners, predecessors, downstream effects, and at-risk work while simulations leave the approved plan unchanged.
Actual product screen
A versioned executive record carries readiness, risks, decisions, dependencies, evidence, and human-review state into one inspectable report.
The North Star
RxLaunchOS is designed for pharmaceutical commercial leaders preparing for a U.S. launch—especially teams with retained rights, a small U.S. organization, and roughly 6–24 months before launch.
It brings the decisions and failure risks that matter into view early enough for leadership to challenge assumptions, strengthen the plan, and act with greater conviction.
The intended experience is their U.S. Commercialization Office—not a project manager, generic CRM, dashboard collection, or ChatGPT wrapper.
Ideal customer profile
The primary fit is an emerging U.S. biopharma, biosimilar company, or global manufacturer preparing a first or early U.S. launch with retained rights, a lean commercial organization, and consequential capabilities still to define.
LaunchOS is especially relevant roughly 6–24 months before launch, when leaders must connect strategy, organization, evidence, partners, field design, data, and execution without pretending every answer is already known.
The manufacturer owns the commercial choices and needs the decision record to remain on its side.
The launch demands institutional discipline before every full-time capability is practical.
Specialty and concentrated HCP/HCO universes make sequencing, targeting, capacity, and access assumptions material.
Organization, field model, CRM, partners, evidence, and timing still have meaningful options and consequences.
One system, different operating jobs
LaunchOS changes the questions, horizon, and roll-up for the job at hand while preserving tenant permissions, reporting relationships, and human decision rights.
Account and 90-day plan
Connect assigned accounts, objectives, stakeholder and barrier facts, evidence, outcomes, and follow-ups to the next purposeful action.
Team, monthly, and quarterly plan
See roster, territory, capacity, coaching evidence, commitments, barriers, and escalations together so the right issue is coached or unblocked.
District and regional plan
Compare authorized district patterns, direct manager attention, and surface resource, sequencing, or strategy pivots without ranking people.
National function plan
Align targets, capability, vendors, channels, evidence, milestones, and cross-functional dependencies to the launch strategy.
Enterprise and portfolio view
See the decisions, tradeoffs, capital implications, launch risks, and weak assumptions that require leadership attention now.
One shared operating record
Work from the same versioned plan while market access, field operations, CRM/data, and launch leadership retain clear ownership and approval.
Executive operating view
01
An executive view of readiness, critical risks, decisions due, and the launch critical path.
02
A traceable assessment that keeps readiness, confidence, hard gates, unanswered questions, and evidence quality distinct.
03
A governed record of what must be decided, what evidence supports it, who owns it, and what delay changes.
04
A launch path shaped by dependencies and decision consequences rather than a generic list of project tasks.
05
Scoped specialist input and build-buy-rent choices connected to the decision that requires them.
06
Explainable outputs and configurable decision methods that remain clear to the leaders responsible for acting.
Transparent plan-quality scoring
LaunchOS evaluates versioned planning objects once, then shows what is covered, what is blocked, which evidence is weak, and which decision or critical-path commitment needs human attention.
When coverage, required gates, or evidence are insufficient, the system suppresses a false overall score and explains what must be resolved. Approved weights and thresholds remain versioned methodology rather than a hidden universal formula.
01
Shows whether the required, authorized inputs are present and current enough to evaluate.
02
Keeps failed or unverified launch gates visible instead of averaging them away.
03
Tests whether material choices have owners, dates, options, consequences, and an explicit state.
04
Separates verified, stale, contradictory, assumed, and missing support for material claims.
05
Connects committed dates and dependencies to the consequence of delay while refusing false precision.
Visible formula state Method version, coverage, gates, blockers, and calculation trace remain beside any approved composite.
Evidence-aware refusal Missing, stale, contradictory, or mixed-grain inputs produce a useful refusal instead of polished fiction.
Human decision boundary AI may explain or challenge the result; it cannot set the score, approve a gate, or make the launch decision.
Scenario simulation
LaunchOS compares explicit options, assumptions, dependencies, tradeoffs, leading indicators, and wait consequences. A simulation is a governed scenario—not a prediction or an automatic recommendation.
Competitive advantage
Enterprise intent flows into role plans, measures, actions, reviews, decisions, reports, and learning without changing who is authorized to see or decide.
Scores, signals, and recommendations remain tied to source, freshness, coverage, confidence, and an explicit insufficient-data state.
Questions, rules, gates, thresholds, evidence requirements, and report structures are configurable and versioned rather than buried in a slide deck or hard-coded screen.
RxLaunchOS helps compare build, buy, rent, partner, and defer choices without acting as a captive CRM, CSO, data vendor, or agency.
Operating provenance
RxLaunchOS translates UEM's pharmaceutical commercialization, launch execution, regulated distribution, and go-to-market systems experience into a configurable, evidence-aware operating system.
Operating commitments
RxLaunchOS is designed to improve commercial judgment without obscuring accountability, evidence, or the interests behind a recommendation.
The manufacturer remains accountable for the launch, the evidence, and the final decision. RxLaunchOS strengthens that control rather than transferring it to a vendor.
Readiness, risks, assumptions, evidence, and decision rationale remain inspectable so leaders can challenge the basis of a recommendation.
The system distinguishes what is known, assumed, missing, or stale and brings qualified specialists into decisions that require deeper judgment.
Build, buy, rent, and partner choices are evaluated from the manufacturer’s side—not shaped by referral fees, placement economics, or a captive delivery model.
AI's role
AI can help structure evidence, summarize complexity, compare options, surface gaps, and prepare decision support. It should not invent facts, silently alter launch state, make unsupported predictions, or conceal uncertainty behind polished language.
What RxLaunchOS will not replace
From evidence to action
RxLaunchOS helps commercial leaders identify the evidence a decision depends on, the assumptions most likely to change the answer, the people who must contribute, and the consequence of waiting.
Launch conversation
UEM will help clarify the decision, the evidence already available, the gaps that remain, and whether RxLaunchOS or a scoped specialist can strengthen the path forward.
Start an RxLaunchOS conversation Or view plans and monthly pricing in RxLaunchOS →Rexa is Upper Echelon Management's public AI concierge. Do not share patient information, passwords, trade secrets, or confidential company information.